RxDoctor Payments Data

Awaneesh Kumar, MD

Internal Medicine · Indianapolis, INNPI 1427557099

Payments from drug & device makers

What this record shows

This record is dominated by grants: $55,000 of the $68,351 with a category attached, or 80.5%. 25 manufacturers reported payments, led by Boston Scientific at 34.7% of the total. 2025 is the largest year on record at $63,552, more than ten times the $875 reported in 2021. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$68,351in general payments, 2019–2025

Across 128 payments — averaging $534.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$24K
  • Medtronic$21K
  • Abbott$17K
  • Biotronik Inc.$3K
  • Biosense Webster, Inc.$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • plus $2K from 19 others

What the payments were for

  • Grants$55,00080%
  • Travel & lodging$4,6197%
  • Food & beverage$7,74111%
  • Education$9911%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,351 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$37,866
Medicare patients
499
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$33,560
JardianceEmpagliflozin11$11,027
Metoprolol Succinate21$416
Losartan Potassium33$285
Chlorthalidone14$240
Rosuvastatin Calcium18$199
Lisinopril18$166
ClopidogrelClopidogrel Bisulfate16$163
Furosemide25$158
Atorvastatin Calcium19$135
Amlodipine Besylate33$133
Metoprolol Tartrate16$58
Carvedilol19$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$22$11,02711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →